Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The compa...
Vor Biopharma 今日盘中大幅走高,截至 ET 09:45 报 19.32 美元,较前收盘 18.39 美元上涨约 5.1%,主要因本周早些时候宣布的 7500 万美元私募融资及 Wedbush 维持正面评级持续发酵。盘中股价从 18.75 美元开盘后迅速拉升,创日内高点 19.32 美元,低点 18.75 美元,成交量 5.5 万股。此前公司核心管线 telitacicept 在中国获批治疗干燥综合症,加之 Wedbush 维持积极展望,提振市场情绪。不过 Q1 净亏损扩大至 2.196 亿美元,同比恶化 576%,且股价仍较 52 周高点 49.95 美元下跌 61%,但 YTD 涨幅达 66%,远高于 MA20(15.16 美元)和 MA60(15.12 美元)。
Market Signals Diverge as AI Infrastructure Expansion Meets Defensive Hedging
Top Biotech Gainers: WGRX Rebrands, PVLA Nears FDA Milestone, ASBP On Track For NDA Filing
RA Capital Healthcare Fund disposes of 213 Vor Biopharma shares worth $4,206.75
Vor Biopharma (NASDAQ:VOR) Stock Price Up 12% - What's Next?
Vor Biopharma Inc. (NASDAQ:VOR) Given Average Recommendation of "Moderate Buy" by Analysts
Vor Biopharma director David Zaccardelli files initial beneficial ownership statement